Genmab A/S (NASDAQ:GMAB) Shares Sold by Sanctuary Advisors LLC

Sanctuary Advisors LLC cut its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 66.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,091 shares of the company's stock after selling 21,709 shares during the quarter. Sanctuary Advisors LLC's holdings in Genmab A/S were worth $220,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Two Sigma Advisers LP increased its position in shares of Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock worth $14,996,000 after acquiring an additional 280,900 shares during the last quarter. FMR LLC increased its holdings in Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after purchasing an additional 33,076 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Genmab A/S by 6.5% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company's stock valued at $5,662,000 after purchasing an additional 14,165 shares in the last quarter. Natixis Advisors LLC boosted its stake in shares of Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock valued at $5,036,000 after buying an additional 47,437 shares during the last quarter. Finally, ABC Arbitrage SA purchased a new position in shares of Genmab A/S during the 4th quarter valued at approximately $3,692,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Up 1.8 %

Genmab A/S stock traded up $0.43 during mid-day trading on Friday, reaching $24.14. The company's stock had a trading volume of 803,338 shares, compared to its average volume of 862,926. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88. The firm has a market cap of $15.98 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 2.65 and a beta of 0.98. The business has a 50 day moving average price of $21.28 and a 200-day moving average price of $22.66.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GMAB has been the subject of a number of research analyst reports. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Finally, HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $42.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.